Further, after we excluded patients with NAFLD, the AST/ALT ratio was still negatively associated with the risk of GDM in the fully adjusted model (OR: 0.22,95% CI: 0.06–0.8) (Table 4). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.